Monday, January 13, 2014
Horizon Discovery, a provider of research tools to support translational genomics research and the development of personalized medicines, and AstraZeneca have entered into a research, collaboration and license agreement to explore oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.
While many drug developers continue to improve clinical trial operational efficiency to increase the pace of new product introductions, their medium- and long-term success increasingly will depend on their ability to embrace more efficient R&D models, according to the Tufts Center for the Study of Drug Development.
MedImmune, AstraZeneca’s global biologics R&D arm, has entered into an oncology research collaboration and licensing agreement with Immunocore, a privately-held, U.K.-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
Epirus Switzerland, a wholly-owned subsidiary of Boston-based Epirus Biopharmaceuticals, and Ranbaxy Laboratories, a division of Daiichi Sankyo, Tokyo, have signed a licensing agreement for BOW015, a biosimilar infliximab, for territories including India, selected South East Asian markets and North Africa.